Onesource Specialty Pharma Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2026 • Contract Development and Manufacturing Organization: 100.0%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Operating margins have improved to 16.7% from -407.9%
- Latest quarter profit grew 106.4% YoY, showing strong momentum
- Working capital cycle has improved - days down from -13 to -17
- Institutional investors have been accumulating - FII+DII up 5.9pp
- Company maintains a comfortable, low leverage position
CONS
- A large part of profit comes from other income (221.3% of PBT)
- Recent results are weak - TTM profit is down 85.3% versus prior year
- Receivables are growing faster than sales - a possible quality concern
- Company has a low return on equity of -20.5% over last 3 years
- Company has a low return on capital employed of -5.2%
- Interest coverage is weak at 1.2x - earnings barely cover interest
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1868.50 | 37.06 | 448315.74 | 0.86 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9482.75 | 86.06 | 251737.22 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4931.90 | 86.01 | 187593.62 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1129.00 | 24.95 | 112618.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1368.00 | 32.79 | 110515.04 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1933.25 | 95.54 | 104455.86 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1690.00 | 26.19 | 97238.86 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2092.00 | 17.30 | 95660.02 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1143.20 | 29.61 | 95420.61 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2266.00 | 45.82 | 93596.02 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2439.55 | 38.29 | 68850.12 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| ONESOURCE | 1530.05 | 368.45 | 17545.53 | 0.00 | 25.00 | 13539.25 | 449.02 | 37.20 | 0.44 | 27.47 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | 56 | 73 | 240 | 245 | 337 | 477 | 321 | 375 | 290 | 419 | 446 | |
| 72 | 67 | 76 | 230 | 222 | 237 | 240 | 241 | 274 | 277 | 344 | 399 | |
| Operating Profit | -38 | -10 | -3 | 10 | 23 | 99 | 237 | 80 | 102 | 13 | 75 | 47 |
| OPM % | -113.32% | -18.38% | -3.65% | 4.27% | 9.35% | 29.54% | 49.63% | 24.88% | 27.07% | 4.42% | 17.83% | 10.63% |
| -5 | -105 | 3 | -1 | -3 | -95 | 4 | 5 | 3 | -2 | 4 | 4 | |
| Interest | 25 | 26 | 20 | 41 | 44 | 44 | 32 | 27 | 33 | 38 | 22 | 31 |
| Depreciation | 18 | 20 | 20 | 34 | 33 | 34 | 34 | 33 | 34 | 35 | 35 | 36 |
| Profit before Tax | -87 | -161 | -40 | -65 | -58 | -73 | 175 | 25 | 37 | -62 | 21 | 51 |
| Tax % | -0.00% | -0.00% | -0.00% | 63.38% | -0.00% | -0.00% | 0.00% | 0.00% | 0.00% | -0.00% | 0.00% | 0.00% |
| Net Profit | -87 | -161 | -40 | -24 | -58 | -73 | 175 | 25 | 37 | -62 | 21 | 51 |
| -27.30 | -38.66 | -9.63 | -2.22 | -5.35 | -6.69 | 15.28 | 2.17 | 3.24 | -5.43 | 1.87 | 4.47 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| 39 | 172 | 1,300 | 1,405 | 1,531 | |
| 199 | 259 | 932 | 1,168 | 1,294 | |
| Operating Profit | -161 | -88 | 367 | 237 | 237 |
| OPM % | -414.89% | -50.91% | 28.26% | 16.87% | 15.45% |
| -156 | -112 | -93 | 42 | 8 | |
| Interest | 48 | 89 | 162 | 121 | 124 |
| Depreciation | 66 | 76 | 135 | 137 | 140 |
| Profit before Tax | -430 | -365 | -21 | 21 | 48 |
| Tax % | -0.00% | -0.00% | 193.22% | 0.00% | 0.00% |
| Net Profit | -430 | -365 | 20 | 21 | 48 |
| EPS | -200.69 | -91.01 | 1.75 | 1.85 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 231%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- -16%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- -20%
- Last Year:
- 0%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 4 | 4 | 11 | 11 |
| 777 | 386 | 5,896 | 5,932 | |
| 858 | 414 | 866 | 1,360 | |
| Trade Payables | 95 | 81 | 160 | 402 |
| 275 | 424 | 456 | 570 | |
| Total Liabilities | 2,008 | 1,309 | 7,390 | 8,276 |
| 1,361 | 863 | 3,200 | 3,198 | |
| Capital Work in Progress | 191 | 43 | 60 | 314 |
| 5 | 20 | 2,848 | 2,931 | |
| 133 | 11 | 153 | 439 | |
| 0 | 55 | 442 | 735 | |
| Cash & Bank | 80 | 60 | 228 | 90 |
| 238 | 257 | 459 | 569 | |
| Total Assets | 2,008 | 1,309 | 7,390 | 8,276 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| -176 | -109 | -47 | 55 | |
| Cash from Investing | -66 | 506 | -300 | -478 |
| Cash from Financing | 118 | -384 | 417 | 361 |
| -112 | 13 | 70 | -61 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-03 - Onesource Specialty Pharma Limited has informed the Exchange about Investor Presentation
2026-09-01 - Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication confirming dispatch of Notice of the 19th Annual GeneralMeeting (AGM) and Remote e-voting
2026-08-31 - Onesource Specialty Pharma Limited has informed the Exchange regarding 'Intimation of Business Responsibility and Sustainability Report for FY 25-26'.
2026-08-31 - Onesource Specialty Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026
2026-08-31 - Onesource Specialty Pharma Limited has informed the Exchange about Schedule of meet
2026-08-29 - Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the 19th AGM of the Company
2026-08-18 - Onesource Specialty Pharma Limited has informed the Exchange about Credit Rating
2026-07-31 - OneSource Specialty Pharma Limited has informed the Exchange about Earnings Call Transcript dated July 25, 2026
2026-07-27 - Onesource Specialty Pharma Limited has informed the Exchange about change in Management
News
Recent coverage and analyst commentary for ONESOURCE
Loading news…
AI Stock Analyst
Onesource Specialty Pharma Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account